title: [Prostate cancer screening: utility, goals and perspectives in 2010].
abstract: According to recent results of a sub-group of 20,000 patients from the ERSPC study, prostate cancer screening significantly increases disease specific survival for men with a life expectancy of 15 years. However presently, only 20% of prostate biopsies lead to the diagnosis of cancer. This low yield may be increased by using new tools on their way to validation, such as the blood and urinary markers p2-PSA and PCA3, so as MRI and tridimensional computerized echography. Finally, the tumours detected must be managed with subtlety, since a third of them are not overtly aggressive clinically. Hence, a significant proportion of such tumours may not need immediate curative intent treatment, and can be followed up in an active surveillance protocol.
authors.affiliation: Service d'urologie, Departement de chirurgie, HUG et Faculté de médecine, Université de Genève. christophe.iselin@hcuge.ch
authors.forename: Christophe
authors.initials: C
authors.lastname: Iselin
authors.forename: Patrice
authors.initials: P
authors.lastname: Jichlinski
mesh_terms: D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control*